---
title: "Cerenome Reports Second Quarter 2026 Financial Results and Business Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295973378.md"
description: "Cerenome reported Q2 2026 results, showing an operating loss of $9.1 million and net loss of $9.0 million, compared to a net income in Q2 2025. Cash reserves stood at $8.6 million. The company rebranded from Plus Therapeutics and highlighted progress in REYOBIQ clinical trials and CNSide assay commercialization, including expanded payer coverage and AI partnerships."
datetime: "2026-08-14T20:17:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295973378.md)
  - [en](https://longbridge.com/en/news/295973378.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295973378.md)
generator: "portal-rs"
---

# Cerenome Reports Second Quarter 2026 Financial Results and Business Update

Cerenome, Inc. (Nasdaq: CNSY), a CNS oncology company based in Houston, released its financial results for the second quarter of 2026, ending on June 30. The Company focuses on precision diagnostics, targeted therapeutics, and artificial intelligence in the field. Cerenome provided insights into recent business developments and upcoming highlights along with this announcement.

### Related Stocks

- [PSTV.US](https://longbridge.com/en/quote/PSTV.US.md)
- [CNSY.US](https://longbridge.com/en/quote/CNSY.US.md)

## Related News & Research

- [Cerenome Launches as an Integrated CNS Oncology Company | PSTV Stock News](https://longbridge.com/en/news/294514925.md)
- [Plus Therapeutics amends bylaws to reflect corporate name change to Cerenome](https://longbridge.com/en/news/294876172.md)
- [AI Was Supposed to Kill Wix. Google Just Gave It a Way to Fight Back.](https://longbridge.com/en/news/297433684.md)
- [AI Winners, Victims, and the One Stock to Sell Now](https://longbridge.com/en/news/297431483.md)
- [The Bull Case For Oracle (ORCL) Could Change Following Its Expanded Clinical AI Agent Rollout](https://longbridge.com/en/news/297431787.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**